-
2024-510908-37-00
5
2024-08-28
KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
-
2023-503923-24-00
5
2024-07-22
Sjögren’s Syndrome With Moderate-toSevere Symptom State
-
2023-509088-26-00
4
2024-07-22
Metastatic colorectal cancer
-
2023-503666-23-00
5
2024-06-07
Neovascular age-related macular degeneration
-
2023-505928-59-00
5
2024-04-15
Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
-
2023-503235-18-00
4
2024-01-31
previously untreated WM
-
2022-501863-41-00
5
2023-11-13
Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
-
2023-508945-41-00
4
2023-10-11
Hepatocellular Carcinoma
-
2022-501176-26-00
5
2023-08-04
Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
-
2022-501576-25-00
5
2023-07-07
Melanoma
-
2022-502145-10-00
5
2023-06-06
Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor
-
2024-514080-25-00
5
2023-04-21
Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary P
-
2024-510742-13-00
5
2023-04-19
Pediatric low-grade glioma harboring an activating RAF alteration requ
-
2023-503444-13-00
5
2023-03-29
Relapsed/refractory multiple myeloma
-
2024-512785-33-00
10
2023-03-01
Active Idiopathic Inflammatory Myopathy (IIM)
-
2023-508740-21-00
4
2023-02-15
Non-Small Cell Lung Cancer
-
2022-500861-29-00
5
2023-01-12
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2023-508284-77-00
5
2022-11-16
Generalized Myasthenia Gravis with autoantibodies against acetylcholin
-
2023-505772-30-00
5
2022-11-09
Melanoma
-
2024-513295-18-00
4
2022-08-10
Relapsed or Refractory Peripheral T-cell Lymphomas
-
2024-511068-10-00
5
2022-08-04
Sjögren’s Syndrome
-
2023-508559-37-00
5
2022-07-14
Lupus nephritis
-
2024-510800-35-00
5
2022-06-17
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2023-507131-38-00
5
2022-05-16
Neovascular Age-Related Macular Degeneration (nAMD)